Continue Your Education

Aimee Martin, MS, CGC from West Cancer Center comments on using genetic testing in Black breast cancer patients: Earlier diagnosis, triple negative cancers, and more aggressive disease linked to BRCA 1/2 gene mutations.

Dr Gregory Vidal, MD, PhD from West Cancer Center highlights on this year’s most impactful developments in breast cancer: The HER2-Low space, efficacy of antibody-drug conjugates, and changing treatment paradigms.

Dr Willaim Gradishar, MD, from Northwestern University Feinberg School of Medicine comments on strategies to retain fertility in young women with breast cancer, and the use of genomic assays to better assess the need for chemotherapy.

Dr Lajos Pusztai, MD, DPhil from Yale School of Medicine comments on the use of molecular tumor profiling in breast cancer: Finding actionable, targetable mutations in PI3K, ESR, BRCA, and others; ctDNA monitoring for molecular recurrence in early breast cancer.

Dr Priyanka Sharma, MD from University of Kansas Cancer Center comments on current hot topics for case discussion in breast cancer: Emerging therapies for endocrine-resistant disease, defining HER-2 Low breast cancer, and re-evaluating treatment in triple negative disease.

Dr Julia White, MD from University of Kansas Cancer Center comments on emerging technologies to determine who benefits from radiation therapy benefit after lumpectomy: Biologic selectors, multi-gene assays, and the POLAR gene assay.

Dr Joyce O’Shaughnessy, MD from Texas Oncology discusses on the evolution of treatment for HR+/HER2- breast cancer: From tamoxifen, to aromatase inhibitors, to CDK 4/6 inhibitors, and inhibitors of endocrine therapy resistance.

Dr Jennifer Klemp, PhD, MPH, MA, from University of Kansas Cancer Center comments on the expanding use of molecular testing in breast cancer: More options available to help guide treatment, and learning how best to apply them.